CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2N141I neurons

Maitane Ortiz-Virumbrales 1, Cesar L. Moreno 1,2, Ilya Kruglikov 3, Paula Marazuela 4, Andrew Sproul 3,5, Samson Jacob 3, Matthew Zimmer 3, Daniel Paul 3, Bin Zhang 6, Eric E. Schadt 6, Michelle E. Ehrlich 1,6,7, Rudolph E. Tanzi 8, Ottavio Arancio 9, Scott Noggle 3* and Sam Gandy 1,2*

Abstract
Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2 (PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2N141I mutation displayed an increase in the Aβ42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2N141I lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2N141I BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased Aβ42/40 was also normalized following CRISPR/Cas9-mediated correction of the PSEN2N141I mutation. The genome editing data confirms the robust consistency of mutation-related changes in Aβ42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.

Keywords: Alzheimer’s disease, iPSC, BFCN, CRISPR/Cas9, Electrophysiology, Basal forebrain, Cholinergic, Presenilin, PSEN2

Introduction
The “amyloid hypothesis” is one of the most popular formulations for the pathogenesis of Alzheimer’s disease (AD). Recent examples of clinicopathological and/or clinical-radiological dissociation have led to the consideration of alternative models in order to explain, respectively, why neuropathological AD is not always associated with dementia [24], and why about one-third of patients with clinical AD have negative amyloid brain scans [40]. It has been proposed that clinical AD can be caused by one of several “feed-forward” scenarios linking amyloidosis, tauopathy, neuroinflammation, and neurodegeneration [22]. Mutations in the gene encoding presenilin 2 (PSEN2) are associated with autosomal dominant early onset familial Alzheimer’s disease (EOFAD). The linkage of a locus on human chromosome 1q31–42 linked to EOFAD led to the identification of the PSEN2N141I point mutation in the Volga German kindreds in 1995 [43]. This mutation causes elevation in the Aβ42–43/40 ratio, thereby promoting assembly of Aβ oligomers and fibrils [83].

In considering the progression of AD, human basal forebrain cholinergic neurons (BFCNs) are one of the first cell types whose dysfunction underlies the early loss of short-term memory recall in all forms of AD. The “cholinergic hypothesis of AD” was formulated in the mid-1970s [6, 20, 61], and the discoveries of reduced acetylcholine release from neurons of the nucleus basalis of Meynert confirmed the
presence of a presynaptic cholinergic deficit in the 
basal forebrain of AD patients [1, 71]. Based on those 
observations, acetylcholinesterase inhibitors were 
developed and continue as the most widely used symp-
tomatic treatments for AD [21, 28, 33, 82]. 
Eventually, post-mortem brain biochemical and vol-
umetric studies at different stages of the disease identi-
fied several other regions of the brain that were also 
affected early in the course of AD [63]. These studies 
have traditionally focused on the hippocampus and 
cortex, but more recently, attention has begun shif-
ting back to the basal forebrain and adding other 
areas, such as the striatum [27, 62]. The latest ana-
lyses suggest that cholinergic basal forebrain volume 
measurement may be a better predictor of the transi-
tion from MCI to AD than the previous standard, 
hippocampal volume [10].

We previously reported the generation of iPSC-derived 
neurons from banked fibroblasts from subjects harbor-
 ing PSEN1^{A246E} and PSEN1^{M146L} mutations [77]. In 
characterizing the gene expression profiles from these 
 iPSC-derived neurons, we observed an unexpected asso-
ciation of elevated expression of the inflammasome gene 
NLRP2 in undifferentiated PSEN1 mutant iPSCs and 
their and neuronally differentiated progeny [77]. This led 
us to examine NLRP2 expression in our PSEN2 mutant 
lines and employ CRISPR/Cas9 [15] to investigate if acti-
vation of the inflammasome was tightly linked to the 
pathogenic mutation in PSEN2. While we did not find 
altered expression of NLRP2 in gene-corrected PSEN2 
lines, we observed significant mutation-related, editing-
reversible differences in excitability of BFCNs.

Materials and methods

Generation and maintenance of iPSC lines

7889(s)B, 050643 (Control), 948 (AD1), 949(fControl), 
and 950 (AD2) iPSC lines were obtained via the NYSCF 
Repository following the guidelines from [60]. The deriv-
ation and characterization of Nkx2.1-GFP ESC line was 
previously published [30]. ES and iPSC cell lines were 
expanded and maintained in serum-free mTeSR1 media 
Stem Cell Technologies). Cells were lifted using 
StemPro Accutase (ThermoFisher) and media was 
previously published [30]. ES and iPSC lines were 
treated with 2% Triton X-100 for a 5-min period in order 
to lyse all cells, and media from these wells was also 
collected and incubated as described. After incubation absorb-
ance was recorded at 490 nm and 680 nm, signal and 
background absorbance, respectively. Signal values were 
subtracted from background, and values were adapted to 
the total LDH content as determined by Triton X-100 
treated wells. Propidium iodide (Thermo Fisher Scientific) 
was added to cell media for a 1 μM final concentration and 
allowed to incubate for 5 min. Cells were then washed 
twice with media and imaged. Images were captured using 
CELIGO image cytometer and accompanying software 
(Nexcelom Bioscience). Each biological variable was 
assessed in technical triplicates within each designated 
“Experiment”, and each designated “Experiment” was per-
formed in at least three complete “start to finish” iterations.

Differentiation of basal forebrain cholinergic neurons 
from iPSC and ES cells

Human ES or iPSC were plated as single cells after chemi-
cal dissociation using Accutase (Sigma-Aldrich) into Cul-
trex (Trevigen) coated plates, at a density of 4–8 × 10⁵ cells 
per well in 6-well plates or petri dishes and adapting cell 
numbers. Cells were initially maintained in mTeSR1 media 
Stem Cell Technologies) until reaching full confluency. On 
“day 0” of differentiation, media was replaced by Custom 
mTeSR1 media (Stem Cell Technologies) lacking factors 
providing pluripotency i.e., bFGF, TGF-Beta, Li-Cl, GABA 
and pipecolic acid. The addition of dual SMAD inhibitors

Aβ42 oligomer preparation

Aβ42 oligomers were prepared as previously reported 
[23, 78]. Briefly, we dissolved 1 mg of Aβ42 (American 
Peptide Company) in 1,1,3,3,3-hexafluoro-2-propanol 
(HFIP) (Sigma). This preparation was aliquoted and 
dried using a SpeedVac centrifuge. The pellet was then 
resuspended in DMSO to obtain a 5 mM solution which 
was sonicated in a water bath for 10 min. From here ali-
quots were stored at -20°C and used within 2 weeks by 
diluting with 100 μl of PBS and leaving for 12 h at 4 °C 
in order for oligomerization to proceed. This final solu-
tion was diluted 1:16 in cell media for studies, allowing 
cells to be exposed to 5 μM of Aβ42 oligomers. Control 
well were diluted with 1:16 PBS. Cells were exposed to 
oligomers or PBS without media change for a period of 
3 days.

Cell death assays

Cells were assayed in a 96-well plate format. Oligomer or 
vaccine solutions were added to media and allowed to incubate for a period of 3 days. Media was then collected and assayed using a lactate dehydrogenase toxicity assay (Thermo Fisher Scientific). 50 μl of media and an equal amount of reaction mix buffer were incubated for a period of 30 min. An additional set of wells per experiment were treated with 2% Triton X-100 for a 5-min period in order to lyse all cells, and media from these wells was also collected and incubated as described. After incubation absorbance was recorded at 490 nm and 680 nm, signal and background absorbance, respectively. Signal values were subtracted from background, and values were adapted to the total LDH content as determined by Triton X-100 treated wells. Propidium iodide (Thermo Fisher Scientific) was added to cell media for a 1 μM final concentration and allowed to incubate for 5 min. Cells were then washed twice with media and imaged. Images were captured using CELIGO image cytometer and accompanying software (Nexcelom Bioscience). Each biological variable was assessed in technical triplicates within each designated “Experiment”, and each designated “Experiment” was performed in at least three complete “start to finish” iterations.
At day 2 of differentiation, media was replaced by custom mTeSR1 containing dual SMAD inhibitors plus two vertralizing agents: SAG at 500 nM (R&D) and Purmorphamine at 2 μM (Stemgent). Cells were fed every 2 days with this media until day 9, when media was progressively switched to Brainphys media (Stemcell Technologies) supplemented with B27 (Life Technologies) [3]. Neural progenitors were harvested at day 11 using Accutase, p75 + (CD271) NPCs with B27 (Life Technologies) [3]. Neural progenitors were to Brainphys media (Stemcell Technologies) supplemented with 20 μM ROCK inhibitor (Y27632, Stemgent), Nerve Growth Factor, NGF, (Alamone labs, 50 ng/mL) and Brain Derived Neurotrophic Factor, BDNE, (R&D, 50 ng/mL). Cells were allowed to aggregate and form Neuronal Embryoid Bodies (NEBs) and were fed every other day until day 19. At day 19 NEBs were dissociated using Accutase (Sigma-Aldrich) and were plated as monolayer cultures on plates coated with branched polyethyleneimine (1%, Sigma-Aldrich) and laminin (10 mg/mL, Life Technology) in Brainphys media + B27 supplement with BDNF and NGF. The media was changed every 2 days until analysis. As an alternative, 3D NEBs were dissected manually into 3–4 pieces for expansion and further grown, or were cryopreserved. Initial versions of the protocol used Neurobasal as a base media instead of BrainPhys.

**Genomic DNA isolation and sequencing**

Genomic DNA was isolated from PSEN2 mutant or control iPSC lines using High Pure PCR Template Preparation Kit (Roche) following manufacturer instructions. Genomic samples were treated with RNase (QIAGEN) prior to amplification. A fragment from exon 5 of PSEN2 containing PSEN2N141I mutation was amplified using the following primers: Forward 5′-CATCAGGCCTTTGCTTCT-3′, Reverse: 5′-CTCACCTTGTAGCAGCGGTACT-3′, generating a 173 bp fragment, regardless of the genotype. For detection of ApoE allelic variants, a fragment of 244 bp was amplified prior to sequencing using the primers: Forward: 5′-TCAGCACGGAGTGGCTGGAGGGCAGGGC-3′, Reverse: 5′-CTGTCCAAGGAGCTGCAGGCTGGTACAC-3′. Both PCR were performed with the following settings: 10 min 94C, 40 cycles (30 s 94C, 20s 62C, 10s 72C) 7 min 72C. PCR products were run in a 2% agarose gel to check the size of the amplified fragment. After amplification, samples were cleaned using EXOSAP-it (Thermo Fisher Scientific) and then sequenced using the following primers: PSEN2 (Forward: 5′-TCAGCATTACACGCGGTTACAC-3′, Reverse: 5′-AGCACCACAAAGAAGATGGT-3′), from [53]; ApoE (Forward: 5′-ATTCGCCCGGGCCTGTGACACGTCAC-3′, Reverse: 5′-CTGTCCAAGGAGCTGGTACACGAGGC-3′), from [36].

**Bold highlight = base of the ssODN that corrects the point mutation**

**CRISPR/Cas9 gene correction**

iAD1 Control and iAD2 Control lines were originated from 948 (AD1) and 950 (AD2) iPSC lines by CRISPR/Cas9-mediated correction of the PSEN2N141IWT heterozygous point mutation to PSEN2N141IWT. g1N141I single guide RNA (sgRNA) was cloned into pSpCas9(BB)-2A–GFP (PX458) vector, generating pSpCas9-g1N141I-GFP vector to direct gene editing to the sequence in exon 5 of PSEN2 where the Volga mutation is located. Single stranded oligonucleotides (ssODN) are efficient templates for the CRISPR/Cas9 correction [13, 66], ssODN#A-N141I (sequence detail below) was used as donor sequence for gene correction. We designed asymmetric ssODN sequences with a long homology arm of 91 bp, and a short homology arm of 36 bp since asymmetrical ssODNs showed a higher efficiency of homology-directed repair using CRISPR/Cas9 [68].

| Sequence Name | Bases | Sequence |
|---------------|-------|----------|
| g1N141I guide RNA F | 25 | /SPhos/CACCCGACCATGACGCTGGCATGCA |
| g1N141I guide RNA R | 25 | /SPhos/AAACCGATGACGCTGATCATGATGC |
| Donor ssODN#A N141I | 127 | GAGAACGCATGCTGGACAGATGCCAGTGG |
|                   |     | CAGGGCCTGCTGCAAGCAGTTGATTAAC |
|                   |     | TGTAGACCCACCAAGAAGATGGTGA |
|                   |     | TAACCACGATGACGCTGGCATGATGA |
|                   |     | EGGTGCTTACGACCCAGGATGT |

The donor sequence and pSpCas9-g1N141I-GFP vector were transduced in the AD1 and AD2 iPSC lines, plated at 50–70% confluency, using Amaxa Human Stem Cell Nucleofector kit (Lonza VPH-5002) and re-plated for recovery. GFP+ cells were sorted in a BD FACSaria Ii Cell Sorter and were seeded at 30–50 cells per well in 96-well format to detect and pick single clones. Positive clones were expanded, qDNA was extracted and analyzed for successful HDR was determined using a custom designed TaqMan genotyping assay with a probe specific for the SNP (dbSNP ID: rs63750215) located in Chr1:227,073,304. Selected clones were analyzed by Sanger sequencing to confirm correction of Chr1:227,073,304 location and discard possible insertions or deletions in the surrounding areas.

**Fluorescence-activated cell sorting (FACS)**

Neural progenitors at day 12 of differentiation were dissociated with Accutase (Sigma-Aldrich) for 5 min at 37C and inactivated in Neurobasal media. Cells were spun at 1000 rpm for 4 min and the pellets were resuspended in FACS buffer (DPBS, 0.5% BSA Fraction V-Solution, 100 U/mL Penicillin-Streptomycin, 0.5%
EDTA and 20 mM Glucose) with PE Mouse anti-human CD271 antibody (clone C40–1457, BD) at 1:100, also known as p75 or NGFR, and incubated for 20 min at room temperature (RT) in the dark. After the incubation time, cells were washed with FACS buffer and the pellet was resuspended in 2 mL of FACS buffer with 10 μM ROCK inhibitor (Y27632, Stemgent). p75 positive cells were purified in a BD FACSRia IiU Cell Sorter and data was analyzed using FlowJo software.

Real-time quantitative polymerase chain reaction (RT-qPCR)

Human iPSC from PSEN2 mutants or control patients were grown in a monolayer and lysed directly in the cell culture wells with RLT buffer. Total RNA purification was performed according to the manufacturer’s instructions. cDNA was synthesized using SuperScript III Reverse Transcriptase (RT) (Invitrogen, Carlsbad, CA). Semiquantitative real-time PCR was performed on StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA) using the primers listed in the table below. We normalized expression levels to GAPDH. The PCR cycling parameters were: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Each biological variable was assessed in technical triplicates within each designated “Experiment”, and each designated “experiment” was performed in at least three complete “start to finish” iterations. Expression levels were normalized to the control line, and results were expressed as AVG ± SEM.

### Gene | Forward Primer 5′-3′ | Reverse Primer 5′-3′
--- | --- | ---
BDNF | TAACCGGCGGAGCAAAAAAGA | GAAGATGGCTTCATGGCCCT
BF1 | AGAAGAACGGCAATGAGA | TTGGAAGGACAGATTTG6C
Nkx2.1 | TAACCGGCGGAGCAAAAAAGA | GAAGATGGCTTCATGGCCCT
NLRP2, A5B9 | From [77] | From [77]
NLRP3 | AGCAATCTCGACCCGCC | CCATGGCAAACAAACTGAC
Tuj1 | GAAGTGTCCTCCAGACATGAA | CTCTTGAGTAGCTGGGATTGAG

Aβ assays

Cells were conditioned for 3 days after day 8 of dual SMAD inhibition to measure secretion of Aβ by neural progenitors in vitro. Aβ levels were quantified using human/rat β amyloid 40 ELISA Kit and β amyloid 42 ELISA Kit high sensitive (Wako). Each biological variable was assessed using technical triplicates within each designated “Experiment”, and each designated “Experiment” was performed in at least three complete “start to finish” iterations.

Immunostaining/ICC

Cells were fixed with PFA 4% directly on the wells of 12, 48 or 96 well plates for 20 min, washed 3 times with DPBS 1× (ThermoFisher). For the staining, cells were incubated in blocking solution (DPBS 1× with 0.1% Triton X-100 plus 5% Donkey serum) for two hours at room temperature. The corresponding primary antibodies were diluted at suitable concentration in blocking solution, and incubated overnight at 4C. The primary antibodies used are represented in (Additional file 1: Table S1). Cells were washed three times with DPBST (DPBS 1× + 0.1% Triton X-100) and suitable secondary antibody was added in blocking solution for 1 h at room temperature. Then cells were washed three times with DPBST and incubated in blocking solution for 1 h at room temperature. After rinsing, the membranes were incubated in blocking solution (DPBS 1× with 0.1% Tween) plus 5% Donkey serum) for two hours at room temperature for nuclear counterstain. Cells were visualized using an inverted fluorescence microscope (Olympus IX71 microscope) or a confocal microscope (Zeiss LSM5 Pascal microscope) under 10×, 20× or 63× magnification. See Additional file 1: Table S1 for complete details of antibodies used in this study.

Western blots

Human iPSC from PSEN2 mutants or control patients were grown in a monolayer and lysed directly in the cell culture wells with RIPA buffer (Thermo Scientific) with protease and phosphatase inhibitors. The protein concentration was measured using the BCA protein assay kit (Thermo Scientific). After protein estimation, 20 μg of cell lysate were separated by SDS-PAGE electrophoresis on a 4–12% Bis-Tris gel (Bolt® protein gels) and transferred onto nitrocellulose membranes by electrophoresis blotting. The membranes were blocked with blocking buffer 1X TBST (tris-buffered saline +0.1% Tween) plus 5% nonfat dry milk for 1 h in agitation at room temperature and washed three times with TBST. After washing, membranes were incubated at 4 °C overnight in agitation, with the primary antibodies against NLRP2 (1:1000), PSEN2 (1:200) or β-actin (1:1000). After rinsing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated suitable secondary antibodies for 1 h at room temperature. Finally, protein bands were visualized with a chemiluminescent reagent according to the manufacturer’s instructions. β-actin was used as loading control.

Electrophysiology

Whole cell patch-clamp recordings were obtained from single neurons between differentiation days 38 and 55. Cells were seeded at low density onto plastic coverslips which were placed in a perfusion based enclosed recording chamber. Neurons were localized using differential interference contrast optics under an Olympus BX61WI.
microscope fitted with a Hamamatsu Orca R² CCD camera. Recordings were carried out at room temperature using MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA, USA). Signals were sampled at 10 kHz and filtered at 6 kHz using a Digidata 1440A analog to digital converter (Molecular Devices). Amplifier control and data acquisition was done using pClamp 10.0 software (Molecular Devices).

During recordings neurons were perfused with oxygenated BrainPhys media (StemCell Technologies Inc). Medium resistance recording pipettes (4–6 MΩ) were filled with an intracellular solution consisting of (in mM) 130 K-glutamate, 10 KCl, 2 Mg-ATP, 0.2 Na-GTP, 0.6 CaCl₂, 2 MgCl₂, 0.6 EGTA, and 5 HEPES titrated to pH 7.1 and osmolarity of 310 mOsm. In some experiments, the intracellular solution also contained 4 mg/mL biocytin (Sigma-Aldrich) for post-hoc identification of individual neurons, which were visualized with streptavidin-conjugated Alexa 488 (Life Sciences) as described elsewhere [42]. After initial break-in, access resistance (Rs) was constantly monitored and recordings were discarded if Rs exceeded 20 MΩ or changed more than 30%. The voltage protocol for compound Na + and K+ currents characterization was as follows: cells were held at −80 mV potential followed by 500 ms steps from −100 mV to 30 mV with 10 mV increment at a frequency of 0.1 Hz. Following transition to current-clamp mode, resting membrane potential was recorded and cells were hyperpolarized by a negative DC current injection to −70 mV to ensure consistency of excitability measurements. Action potentials were evoked with square 1 s current steps from −10 pA to 40 pA with 1pA steps.

Electrophysiological recordings were analyzed using ClampFit software (Molecular Devices, Sunnyvale, CA, USA) and statistical significance of the results was measured using ANOVA test with Tukey’s post-hoc comparison of means. Salts and other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Statistical analysis
qPCR gene expression experiments and Aβ42/40 ELISAs were analyzed for statistical significance using Student t-test. LDH Release assays were analyzed by 2-Way ANOVA Bonferroni post hoc tests. ANOVA test with Tukey’s post hoc comparisons were used for analysis of electrophysiology results. The experiments needed to study each of the 94 neurons recorded for electrophysiology analyses required days to weeks. On each experimental day, representatives from each genotype were included, with at least three samples from each genotype studied on each day. *, p < .05; **, p < .01; ***, p < .001.

Results
Optimization of protocol for BFCN differentiation
The scheme of BFCN differentiation is described in Fig. 1a. iPSCs from control subjects or AD patients were plated in feeder-free conditions and allowed to reach 100% confluency prior to differentiation using mTeSR1 basal media. Both branches of TGFbeta signaling were inhibited (dual SMAD inhibition) to induce neuroectodermal fate on “day 0” [12]. Differentiations (day 2–10) were performed using a modified mTeSR1 formulation, lacking factors that support pluripotency (bFGF, TGF-Beta, Li-Cl, GABA and pipelicotic acid). To specify these cells to basal forebrain cholinergic neurons, ventralization for medial ganglionic eminences (MGE) induction is required [19, 85, 91]. As such cells were treated with the Sonic Hedgehog (Shh) analog (SAG) at 500 nM and Purmorphamine at 2 μM from days 2 to 8. SAG is a suitable substitute to activate Shh signaling, as demonstrated during differentiation of ChAT+ motor neurons and glutamatergic interneurons [91], with lower cost than recombinant Shh and some advantages in neuronal survival properties over Shh itself [7, 35]. We used the Nkx2.1-GFP embryonic stem cell (ESC) reporter line as a tool to adjust the combination, dosage and timing of ventralizing agents more beneficial for specification of BFCNs from induced Nkx2.1 basal forebrain precursors. However, given the potential of Nkx2.1 intermediate neural precursors to generate multiple neuronal subtypes, such as TH+ and GABA+ hypothalamic neurons, we analyzed the expression of the downstream cholinergic specification factor Lhx8 over expression of the GABAergic interneuron specific transcription factor Lhx6 [26] under different specification conditions (Fig. 1b). These data agree with those from [50] supporting the existence of a synergistic effect of SAG and purmorphamine on Nkx2.1 induction although an effect that is less than the effect of Shh plus purmorphamine (Fig. 1b). Nkx2.1-driven GFP levels were maintained after Day 14, even after withdrawal of SAG + purmorphamine at day 8 (Fig. 1b). We observed higher Lhx8 induction upon SAG plus purmorphamine treatment than SAG alone, or even Shh plus purmorphamine (Fig. 1b). Interestingly, intermediate Nkx2.1 levels driven by SAG plus purmorphamine correlate with higher induction of Lhx8 and BF1 gene expression (Fig. 1b). Our choice of starting SHH pathway-driven ventralization at day 2 was based on reports demonstrating other MGE-derived populations being generated by earlier (e.g., hypothalamic neurons) or later (e.g., GABAergic interneurons) ventralization in the context of dual smad inhibition protocols.

Following the patterning stage, we gradually switched from Custom mTESR1 media to Brainphys media with B-27 supplement to support neuronal survival and growth [3]. At day 11, we observed neural rosettes positive for Nestin and Sox2 markers (Fig. 1c); also, we observed TuJ1+ neurites as early as day 11 (Fig. 1c). To
to obtain cholinergic populations of a higher purity, we developed a P75+ FACS strategy to isolate progenitors specific for cholinergic neurons due to the fact that BFCNs are the only CNS neuron type to express robust levels of P75 under non-pathogenic conditions in the adult brain. Support for this strategy includes a previously published protocol using FACS to isolate high expressing P75+ cells from the embryonic murine septum [65]. This population correlated with best expression of cholinergic-related markers.
At day11/12, we lifted the cells using chemical dissociation (Accutase) and purified day 11–12 p75+ (CD271) neural progenitors and generated 3D neuronal embryoid bodies (NEBs) by spinning down neural progenitors in V-bottom 96 well plates. On day 19 NEBs were dissociated and re-plated as a monolayer on plates coated with branched polyethyleneimine (Aldrich catalog number 408727) and laminin. Monolayer cultures were maintained with the addition of growth factors BDNF, NGF and protease inhibitor DAPT until day 26, when cultures no longer had DAPT added. Immunostaining of both cryosections of NEB structures and fixed
monolayers, resulting from chemical dissociation of NEBs from several control iPSC and H9 hESC lines, demonstrated expression of BFCN lineage markers TuJ1, MAP2, BF1, Nkx2.1 and p75, at final stages of the differentiation protocol (Fig. 1d). NGF addition to neuronal cultures showed an advantageous effect on maturation, neurite outgrowth and presence of ChAT (Fig. 1e).

**Generation and QC of PSEN2\textsuperscript{N141I} iPSC lines**

PSEN2\textsuperscript{N141I} mutant iPSC and control lines were generated from fresh skin biopsies. Established fibroblast lines were grown from skin punches donated by a kindred of 2 carriers for presenilin 2 Volga familial AD mutation (PSEN2\textsuperscript{N141I}) and one non-affected member. Additionally, we included a non-family related control. Fibroblasts were reprogrammed using modified RNA method to introduce the Yamanaka factors (Oct4, KLF4, SOX2 and c-Myc), and the iPSC lines obtained were subject to several quality control processes to ensure robust cell-renewal and pluripotency, including alkaline-phosphatase (AP) enzymatic activity, gene expression analysis and immunostaining for pluripotency markers, as well as karyotyping for detection of chromosome abnormalities, following the automated iPSC reprogramming and QC methods developed by [60]. A summary of the genotypes, sex and age of the subjects included in the study is shown in Fig. 2a. The two PSEN2\textsuperscript{N141I} iPSC lines were also heterozygous for APOE ε4 (ε3/ε4), whereas the control iPSC lines were homozygous ε3/ε3. The characterization of the iPSC lines, expression of pluripotency markers and quality control results are shown in Additional file 2: Figure S1. Briefly, all iPSC clones selected demonstrated pluripotency by embryoid body formation and differentiation into the three germ layers (Additional file 2: Figure S1A). Finally, the lines were fingerprinted (Cell Line Genetics) to ensure they matched the parental fibroblast lines (data not shown). All the parental fibroblast lines and the iPSC lines were subject to Sanger sequencing to determine PSEN2 and APOE genotypes. A 173 bp fragment from the exon 5 of PSEN2, surrounding the area where the PSEN2\textsuperscript{N141I} point mutation is located (Chr1:227,073,304 A > T), was amplified by PCR and sequenced using the primers published in [53]; similarly a fragment of 244 bp from APOE locus that contains two SNPs which determine the three allelic variants was amplified by PCR from genomic DNA, and subsequently sequenced to distinguish between ε2/ε3/ε4 variants, using the primers from [36]. Sample chromatograms showing the presence of PSEN2\textsuperscript{N141I} point mutation are shown in Fig. 2b, and all genotypes are summarized in Fig. 2a.

**Characterization of PSEN2\textsuperscript{N141I} neural progenitors**

To study the effect of the PSEN2\textsuperscript{N141I} mutation in early stages of the differentiation of cholinergic neurons, we analyzed the neural progenitors (NPCs) obtained at DIV 11–16 along the BFCN differentiation protocol. The analysis of this intermediate immature population allows us to detect possible early alterations in the generation of BFCNs that would otherwise not be detected in terminally differentiated cholinergic neurons. Such defects could potentially play roles in mature neurons and contribute to the pathophysiology of AD. We analyzed the expression of early neuronal markers in PSEN2\textsuperscript{N141I} mutant and control NPCs by gene expression and immunofluorescence methods. Although, we found a lower RNA expression of TuJ1 (βIII-Tubulin), a general neuronal marker, in mutant NPCs at day 11 of differentiation, we did not detected quantifiable differences by immunocytochemistry circa days 16–21, (Fig. 2c and d). NPC monolayer cultures at day 11 were also immunostained for typical NPC markers: Sox2, and Pax6; with Pax6 levels dropping as expected along with Nkx2.1 induction (not shown). We observed comparable expression of Sox2 and Nestin in PSEN2\textsuperscript{N141I} cultures at day 11 (Fig. 2c, top panel). At day 21, mutant NPCs expressed comparable levels of Nkx2.1 (MGE marker), but reduced levels of BF1 (forebrain marker) by qPCR; however, BF1 protein expression did not seem affected by immunostaining at this differentiation stage (Fig. 2c bottom panel, and d). We did not observe differences in the surface expression of NGFR (p75/CD271) in DIV11–12 PSEN2\textsuperscript{N141I} cells, in terms of percentage of positive cells or fluorescence mean peak value (Fig. 2e).

As previously published by [59, 73], the expression of mutant PSEN2\textsuperscript{N141I} causes an increase in the Aβ42/40 ratio in the brains of transgenic mice; additionally, this enhanced Aβ42 production was observed in neural cell lines upon induced overexpression of mutant PSEN2\textsuperscript{N141I} protein [83] and in iPSC derived from PSEN2\textsuperscript{N141I} mutant patients [93]. Consistently, we observed a 2-fold increase in the Aβ42/40 ratio, a 50% increase in the amount of secreted Aβ40 and 2.5-fold increase in Aβ42 species in the conditioned media from PSEN2\textsuperscript{N141I} neural progenitors at DIV 11 (**p < 0.001) (Fig. 2e). The levels of secreted Aβ40 and 42 observed in our study and the levels found in [93], using a different neuronal differentiation method applied to FAD1/PS2 iPSC lines derived from fibroblasts from the Coriell repository are very similar in both absolute number and fold-increase.

**Characterization of mature BFCNs from PSEN2\textsuperscript{N141I} iPSC lines and controls**

With the aim of determining the impact of PSEN2\textsuperscript{N141I} mutation on the differentiation, gene expression, function, and communication of BFCNs, we characterized cells at later time points for appropriate expression markers; our goal was to explore whether PSEN2\textsuperscript{N141I} iPSC were able to complete BFCN maturation process and if so, if any abnormalities along later stages of BFCN differentiation may account for the pathophysiology of EOFAD (Fig. 3). In
addition to p75, which preferentially binds pro-NGF, we
analyzed the expression of TrkA, the primary mature NGF
receptor, was also expressed in PSEN2<sup>N141I</sup> BFCNs and
control (Fig. 3a). This suggested that PSEN2<sup>N141I</sup> BFCNs
are susceptible to receiving and benefiting from NGF pro-
survival and differentiation signals as expected and further
confirms their proper identity. We observed comparable
expression of additional cholinergic neuron specific
markers choline acetyltransferase (ChAT) and vesicular
acetylcholine transporter (vAChT) in PSEN2<sup>N141I</sup> BFCNs
and controls (Fig. 3b). Other general neuronal markers
such as Tuj1, and the mature marker microtubule-
associated protein 2 (MAP2) showed no apparent differ-
ences by immunofluorescence (Fig. 3b).

**CRISPR/Cas9-mediated correction of PSEN2<sup>N141I</sup> mutation
and effect on Aβ 42/40 ratio**

To determine if the molecular alterations in the processing
and cleavage of APP and/or the exacerbated activation of
NLRP2 inflammasome, as previously observed in PSEN1
mutants [77], can be attributed to PSEN2<sup>N141I</sup> mutation only,
we modified the PSEN2 locus in our iPSC lines
employing CRISPR/Cas9 technology. We did this by
correcting the PSEN2<sup>N141I</sup> point mutation in the two
PSEN2 mutant iPSC lines (AD1, AD2). For this purpose, a
specific guide RNA (g1N141I) was designed using an
online tool (http://tools.genome-engineering.org) to direct
Cas9 to the region of PSEN2 exon 5 surrounding
PSEN2<sup>N141I</sup> mutation (23 bp upstream of Chr1:227,073,304
A > T). g1N141I was cloned into pSpCas9(BB)-2A
–GFP (PX458) vector. Expression was assessed by GFP
fluorescence upon transfection of pSpCas9-g1N141I-GFP
in HEK293T (Fig. 4a).

In order to correct the mutation, we designed an
asymmetric ssODN HDR (homology directed repair)
template, ssODN#A-N141I, with a long homology arm of
91 bp, and a short homology arm of 36 bp since
asymmetrical donor sequences with a shorter arm
oriented to the area closer to the PAM side demonstrated
a superior efficiency of homology-directed repair using
CRISPR/Cas9 system [13]. We then proceeded to trans-
duce pSpCas9-g1N141I-GFP and ssODN#A-N141I into
the iPSC lines using Amaxa nucleofection (Fig. 4a). Forty-
eight hours post-nucleofection cells were dissociated and
the GFP + population was purified by FACS and replated
at low density feeder free for isolation of single gene-
corrected clones (Fig. 4b). Subsequently, clones were
grown and gDNA extracted post expansion. The screening
of positive clones that demonstrated successful HDR was
determined by qPCR using a custom designed TaqMan
genotyping assay with a probe specific for the SNP (dbSNP ID: rs63750215) located in Chr1:227,073,304 A > T. We were able to distinguish by this method between homozygous PSEN2N141I, heterozygous PSEN2N141I and PSEN2WT single clones derived from the original iPSC lines, and pre-selected clones were subjected to Sanger sequencing to confirm Chr1:227,073,304 location and detect possible insertions, deletions or mismatches introduced by CRISPR/Cas9 modification in the surrounding area and corroborate successful HDR (Fig. 4c).

Successfully corrected clones were expanded and subjected to the BFCN differentiation protocol in parallel to the other 4 lines used in the study. We collected media from BFCNs (DIV 34) and re-tested for amyloid beta production. In support of our previous finding in NPCs at DIV11–12 (Fig. 2f), we observed that mature BFCNs also display significant increases in Aβ42/40 ratio (Fig. 4d) and overall Aβ production (Additional file 3: Figure S2). Importantly, these results also showed a normalization of Aβ42/40 ratio to control levels in corrected lines (iAD1 Control and iAD2 Control, are corrected clones of AD1 and AD2, respectively) (Fig. 4d). These results also strengthen previous findings linking the PSEN2N141I

![Fig. 4](image-url)
mutation to abnormal APP processing and reinforcing that presenilins contain the catalytic site of γ-secretase [90].

Assessment of sensitivity to Aβ42 oligomer toxicity in iPSC-derived PSEN2N141I neurons

Previous reports have shown that iPSC lines carrying FAD mutations may display an enhanced susceptibility to noxious stimuli, such as high concentrations of Aβ42 oligomers [2]. We therefore tested whether our BFCNs from PSEN2N141I mutants would display enhanced toxicity to Aβ42 oligomers in the media (Fig. 5). We assessed neurotoxicity by measuring the percentage of lactate dehydrogenase (LDH) released by dead cells, thus providing an indirect measurement for toxicity. Using this methodology by 2-way ANOVA we detected a significant effect in toxicity driven by 5 μM Aβ42 oligomer addition to the culture media, after 72-h exposure (**, p < 0.01). Post hoc Bonferroni analysis revealed significant differences between the AD2 line and its corrected isogenic control (iAD2 Control). However, this apparent enhanced sensitivity to Aβ42 oligomer toxicity was not observed in the AD1 line and its corresponding control. These results indicate that differences in susceptibility to Aβ42 are not exclusively linked to mutant PSEN2 genotype, and that likely additional genetic factors different between AD1 and AD2 subjects affect susceptibility to this stress, further emphasizing the importance of multiple isogenic models.

Assessment of NLRP2 mRNA in iPSC-derived PSEN2N141I neurons

We previously reported that NLRP2 mRNA was elevated in PSEN1 mutant iPSC and NPCs, [77] which was also the case for PSEN1 mutant cortical neurons (unpublished observation). Therefore, we wanted to analyze the status of the components of the inflammasome in the context of PSEN2N141I mutation. When we assayed by qPCR the mRNA levels of NLRP2 in NPCs at DIV12, we observed an increase over 100-fold in AD1 and AD2 lines, as compared to control lines (Fig. 6a). This correlated with a notable increase in NLRP2 protein, as observed by SDS-PAGE in whole cell lysates from day 11 PSEN2 mutants (Fig. 6d). Noticeably, however we did not detect bands for NLRP2 by immunoblot in the AD2 line lysates. Further, we were unable to corroborate some other transcriptional events previously seen in PSEN1 mutant iPSC neural precursors, such as the elevated ASB9 that encodes an E3 ligase that directs mitochondrial creatine kinase for degradation. Instead, we observed a trend toward decreased levels in PSEN2 mutation carriers by 20–30%.

![Fig. 5 BFCNs carrying various PSEN mutations are not consistently more susceptible to Aβ42 oligomer toxicity. A Sample images of BFCNs from the indicated genotypes treated with propidium iodide to visualize cell death in response to 72-h exposure to Aβ42 oligomers (5 μM). B % LDH Release recorded from media collected after 72-h exposure. n = 3, 3 independent experiments with technical triplicates. *, p < .05; **, p < .01 as detected by 2-Way ANOVA Bonferroni post hoc tests](image)
Assessment of excitability of iPSC-derived PSEN2N141I BFCNs

Using BFCN differentiation protocol, we were able to generate electrophysiologically active cholinergic neurons in a dish from two PSEN2N141I mutant AD patients, wild-type and familial controls starting from differentiation day 35. We were initially unable to obtain mature action potential waveforms from BFCNs grown in Neurobasal media at this stage, but switching to BrainPhys media significantly improved electrophysiological properties of cultured neurons [3]. These findings are in line with electrophysiological characterization of other iPSC generated neurons used to compare both media [3]. We have also replicated the benefits of our protocol containing BrainPhys media in two additional cell lines (including the H9 embryonic stem cell line) with comparable endpoint expression of ChAT and VACHT as well as electrophysiological responses (data not shown).

In order to investigate the electrophysiological properties of BFCN, we recorded from a total of 94 neurons (22 wild-type control, 21 familial control, 18 AD1, 28 AD2 and 5 iAD1 control) using whole cell patch-clamp method. In all experimental groups, recorded neurons displayed voltage-activated currents through sodium and potassium ion channels, ability to generate action potentials and displayed classical neuronal morphologies (Fig. 7). In subset of experiments, recorded neurons were labeled with biocytin through a patch pipette, which allowed for post hoc cell identification and ICH characterization. We found that all biocytin-labelled cells were also immuno-positive for ChAT and VAChT (n = 12, Fig. 8a).

We did not observe significant differences between the groups in terms of neuronal membrane resistance and capacitance, membrane resting potential and the minimum current required for generation of a single action potential (Fig. 9). However, we observed significant mutation-related, editing-reversible differences in excitability of BFCNs.
Neurons derived from AD1 and AD2 lines (as compared to WT and familial controls) were able to generate fewer maximum number of spikes in response to a square depolarizing current injection (ANOVA test with Tukey’s post hoc comparisons, Fig. 8b, c). Height of the first action potential at rheobase current injection was also significantly decreased in AD1 and AD2 BFCNs (Fig. 1c). Importantly, CRISPR/Cas9 correction of the PSEN2 point mutation in the AD1 mutant iPSC line abolished the observed electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in wild-type and familial controls (ANOVA test with Tukey’s post hoc comparisons, Fig. 8).

Discussion

There are 5 million people currently affected by Alzheimer’s disease in the US and, according to the Alzheimer’s Association, this number will increase to 16 million by the year 2050. Unfortunately, we only have direct evidence for genetic causation that accounts for 3–5% of these patients. This percentage encompasses the EOFAD variants, caused by inherited fully penetrant autosomal dominant mutations in the amyloid protein precursor (APP), or PSEN1, PSEN2 that constitute the γ-secretase apparatus [87], and changes in their function increases the production of Aβ42 oligomers and/or deposition of amyloid plaques.

After decades studying murine models of AD that do not fully recapitulate the pathophysiology of this disease in the human brain [5, 57, 58], a complementary new concept of AD modeling in vitro has emerged upon the breakthrough by [81] allowing adult human tissue reprogramming into iPSC using defined factors, and their subsequent in vitro differentiation into specific brain cell types.

BFCNs are one of the most vulnerable neuronal populations whose deterioration explains, in part, the cognitive decline in AD patients. Apart from the evidence for BFCN failure and atrophy, other studies have revealed that human embryonic stem cell-derived BFCNs transplanted into AD mouse models can be associated with improvement in the learning behavior of the implanted mouse [94]. These findings highlight the relevance of iPSC- and ESC-derived BFCNs as not only early clinical indicators but also as a potential strategy for subtype-specific cell-based therapy for AD [39]. In order to move this cell-based therapeutic strategy forward, there has been an urgent need for a refined differentiation protocol to generate human ESC- and/or iPSC-derived BFCNs.

Our first goal was to develop an improved protocol for the generation of BFCNs and intermediate neural progenitors (NPCs), followed by the use of these methods when differentiating cell lines from both control subjects and those harboring the PSEN2 N141I mutation. Using fibroblasts isolated from 3 sisters, 2 carrying the PSEN2 mutation and displaying cognitive decline, with the third wild-type for the mutation, iPSCs were developed [60]. In order to approach the dissection of the fidelity of linkage of various phenotypes to the pathogenic mutation, we began by optimizing published

![Fig. 7 Electrophysiological and morphological features of BFCN.](image)
BFCNs protocols [4, 17, 46, 50, 89] including the purification of an intermediate CD271* (p75) forebrain progenitor population by Fluorescence Activated Cell Sorting (FACS) to generate 3D ventralized neural embryoid bodies (NEBs), which can be later dissociated to look at neuronal populations in a monolayer.

After induction of BFCN differentiation in these cell lines, we have analyzed: (1) capacity to generate TuJ1+/β1+/ChAT+ neurons in vitro; (2) expression of genes/proteins of interest related to neuronal differentiation or inflammation; (3) generation of soluble and oligomeric Aβ40 and 42; (4) electrophysiological (ePhys) properties; and (5) selective vulnerability of BFCNs to one or more innate or microenvironmental factors within or in close approximation to those cells.

Several studies in AD mouse models highlight electrophysiological defects associated to late stages of AD pathology. Synaptic function in the hippocampus was reduced in APP23 mouse models [70]. Similarly, cholinergic neurons from the prefrontal cortex of TgCRND8 mice are unable to sustain cholinergic excitation as compared to control mice [64]. Here we report deficient electrophysiological properties in PSEN2N141I iPSC-derived BFCNs in vitro. Notably, correction of this point mutation re-established neuronal excitability to the level of the control iPSC-derived neurons.

We have optimized an in vitro BFCN differentiation protocol from human iPSC, focusing on generating a homogeneous population of electrophysiologically active ChAT+/VAChT+ neurons in a reproducible and fast way. The innovations introduced to the protocol granted a homogeneous expression of Nkx2.1, a transcriptional marker for MGE subregions, as soon as day 8 and very robust by day 11, compared to day 20 suggested in previously published protocols [38]: in defined serum-free media conditions and without forcing overexpression of factors implicated in cholinergic fate. We were able to record mature action potentials in neurons from day 38 in culture, accompanying co-expression of cholinergic specific markers, which is an earlier time point as compared to other existing protocols using ES or iPSC [4, 17, 46, 50, 89]. Therefore, our protocol has potential application to high-throughput drug screening in homogeneous cholinergic cultures. In addition, the 3D structure of NEBs themselves if left undissociated organoid form would also allow mechanistic analysis in a more physiological setting.

After applying this optimized protocol to PSEN2N141I mutant iPSC lines, we found an increase in Aβ42/40 ratio in the conditioned media. We did not observe any evident defects in the neuronal differentiation process and expression of BFCN markers. Interestingly, we observed a decrease on BDNF gene expression in PSEN2N141I NPCs, similar to results described in a report [18] wherein BDNF changes were observed in homozygous and heterozygous APPswe/PSEN1M146V mice. The two mutant lines are also carriers of one APOE ε4 allele. The presence of this allelic variant, the most common and well characterized risk factor polymorphism for LOAD [16], may modulate the age of onset and severity of the phenotype [49]. Therefore, these iPSC lines combining both the EOFAD PSEN2 Volga mutation (or CRISPR/Cas9 corrected) and APOE ε4 allele constitute a tremendously useful tool to study the pathophysiology of early onset AD in vitro, especially when apoE-secreting iPSC-derived astrocytes are also present.

Searching for adjacent mechanisms or events that may be a cause or a consequence of elevated β-amyloid production, researchers have found overactivated inflammatory and electrophysiological defects associated with AD mutations. The concept of these defects being independent from β-amyloid deposition and their demonstration using CRISPR/Cas9 technology to correct EOFAD mutations would open the debate to the need of combined AD treatments not only targeting β-amyloid plaques (Gandy et al., in press), but also to overcome parallel inflammatory processes or excitotoxicity/defective neuronal firing.

NLRPs are components of the inflammasome, which induces the secretion of mature pro-inflammatory cytokine IL-1β in response to pathogens and toxic stimuli [11, 41]. NLRP2 appears dysregulated in astrocytes [45, 51], and NLRP3 in microglia [34] in the context of Alzheimer’s disease as well as in other neurological diseases like Parkinson’s disease [14, 32]; additionally, NLRP2/3 are altered in pathologies that show comorbidity with AD: obesity, type-2 diabetes. We previously reported an unexpected association of elevated expression of the inflammasome gene NLRP2 in iPSC-derived neurons from banked fibroblasts from subjects harboring PSEN1A246E and PSEN1M146L mutations [77]. This association reminded us of the association of the inflammatory skin disease acne inversa (AI) with mutations in presenilin 1, nicastrin, APH-1 and PEN-2, raising in our minds the question of whether some γ-secretase component mutations might be associated not only with proamyloïdigenic actions but also with proinflammatory mechanisms.

Despite our observations PSEN2N141I mutant cells had elevated NLRP2 compared to controls, we were not able to attribute this upregulation to the familial PSEN2 mutation, as gene correction did not significantly reduce NLRP2 levels. Our results suggest that, although inflammasome dysregulation may occur in the brains of EOFAD patients, there may be factors triggering this event apart from any effect of PSENs on inflammasome biology that are reflected in reprogrammed PSEN2 mutant cell lines. Some potential explanations for this
PSEN2-independent NLRP2 upregulation include effects of the apoE4 allele present in both PSEN2 subjects (not preset in controls) or epigenetic effects on fibroblasts collected from the EOFAD subjects that are maintained through the reprogramming process.

Electrophysiological defects in neurons have been associated with PSEN1 and PSEN2 mutations. Some of these defects are attributed to altered function of voltage-gated K+ channels, potentially through the cleavage of channel components mediated by the PS/γ-secretase apparatus [44, 72]. Presenilin mutations also disrupt calcium signaling by increasing the levels of calcium stored in the endoplasmic reticulum that result in increased stimulus-induced released into the cytosol,

Fig. 8 Electrophysiological deficits in BFCNs from AD lines. a Co-localization of biocytin-labelled neurons (green) with cholinergic markers ChAT (red) and VACHT (blue). Arrows indicate positions of recorded neurons somas, scale bar is 50 μm. b Representative firing patterns of BFCNs produced by a 1 sec negative and positive square current injection are depicted. A grand total of 94 individual neurons were studied electrophysiologically: 22 wild-type control neurons, 21 familial control neurons, 18 AD1 neurons, 28 AD2 neurons, and 5 iAD1_ (CRISPR-corrected) neurons. The experiments on the 94 neurons required days to weeks. On each experimental day, representatives from each genotype were included, with at least three samples from each genotype studied each day. c Summary data on maximum number of action potentials that neurons are capable of sustaining (left) and height of a single action potential at rheobase (right) across all conditions. Individual data points are shown as circles, group means are shown as bars. **, p < 0.01 Tukey HSD test
rather than altered influx of calcium. One of the mechanisms behind neuronal calcium dysregulation was described in cortical neurons from PSEN1M146V mice, mediated by inositol triphosphate (IP3) [79]; and, more directly, the formation of dual function protein-ion channels by unprocessed PSEN1 and PSEN2 themselves, modulating the exit of calcium from the endoplasmic reticulum [29, 55, 80, 84]. Given the important role of presenilins on potassium and calcium flux and neuronal excitability, mutations in PSEN1 and PSEN2 may lead to reduced neuronal excitability and neurotoxicity. Mice carrying mutant forms of APP exhibited aberrant action potentials associated to a decrease in sodium currents with no alteration in potassium currents, only after plaque burden was considerable [9]. There is evidence that APP overexpression causes hyperexcitability in mouse cortical neurons [75, 86, 92].

Mucke and Selkoe [52] have highlighted a toxic effect of Aβ resulting in synaptic and network dysfunction. In fibroblasts and neural cell lines, Aβ-mediated accumulation of mitochondrial Ca\(^{2+}\) was elevated when mutant forms of PS1 were expressed [31]. Neuronal firing patterns in mouse hippocampal neurons were altered by exposure to Aβ [67, 69]. Aβ exposure was also associated with altered K\(^+\) channel conductance in pyramidal neurons [54]. PSEN1 mutations have been observed to associate with altered Ca\(^{2+}\) mitochondrial channels in the cerebellum, apparently causing reduced spike activity in Purkinje cells in the absence of amyloid plaque deposition [74]. Aβ42 may accentuate the defects present in Ca\(^{2+}\) homeostasis by modulation of additional voltage-dependent ion channels [8, 25, 76, 88].

Apart from mouse data and immortalized neuronal cell lines, electrophysiological defects in iPSC-derived neurons upon exposure to Aβ have been shown: hiPSC-derived cortical pyramidal neurons and GABAergic interneurons have deficient action potentials upon exposure to Aβ [56], and neurons differentiated from hiPSC harboring PS1A426E mutation also showed deficient firing patterns [47]. However, there are no previously published data on characterization of electrophysiological properties of PSEN2 mutant iPSC-derived BFCNs.

Hyper- or hypoexcitatory effects and differences in firing frequency vary with the gene mutation and are highly dependent on the neuronal subtype [37, 48]. All these events may contribute to the progressive neurodegeneration present in the pathogenesis of AD, and we specifically document events that may account for the neuronal defects associated to early stages of EOFAD human pathogenesis. Here we report defective electrophysiological properties in iPSC-derived BFCNs that are specifically associated with the PSEN2N141I familial
mutation. Interestingly, although some of the previous studies attribute this impairment in neuronal activity to the build-up of plaques in the brain of AD mice, we found a substantial impairment in the induced action potentials in the absence of amyloid plaques, solely in the presence of a discrete excess of Aβ42 oligomers in the culture media, consistent with other reports [18]. Correction of this point mutation re-established the firing patterns to those of the wildtype iPSC-derived neurons.

Modulators of potassium channels in neurons have proven efficacy in memory improvement in AD mouse models [44]. Modulation of Ca
sup+ channels and excitotoxicity may open a new wave of AD drugs. Understanding the mechanism through which PSEN2 mutations affect the electrophysiological activity in different subsets of neuronal populations and unraveling the connection between PSEN2, other genetic modulatory factors and inflammation will potentially lead to, not only alternative symptomatic treatments, but also to novel drugs decreasing the Ca
sup+ -mediated vulnerability to ROS and potentially stopping the neuronal loss and progression of the disease, if administered at early stages.

It is clear that mutant presenilins alter neuronal excitability even before the formation of Aβ plaques [18, 74]. One plausible hypothesis is that APP and presenilins may exert effects that modulate neuronal excitability through currently unrecognized mechanisms acting separate from their roles in the biogenesis of Aβ. Accumulation of Aβ could synergize with the altered electrophysiological mechanisms in a pathway leading to AD. With the wealth of data supporting neuronal excitability as a key mechanism implicated in AD, further studies focusing on clarifying the possible role(s) of PSENs and/or Aβ in physiological or pathological events are warranted.

**Conclusions**

We have optimized an in vitro protocol to generate human BFCNs from iPSCs from presenilin 2 (PSEN2) mutation carriers and controls. As expected, PSEN2N141I was associated with an increase in the Aβ42/40 in iPSC-derived BFCNs, and this was reversed by CRISPR/Cas9-mediated gene editing. Unexpectedly, iPSC-derived BFCNs or cortical neurons from PSEN2N141I carriers showed diminished basal excitability as quantified by a reduction of both spike frequency and spike amplitude. This electrophysiological phenotype was also abolished following CRISPR/Cas9 correction of the PSEN2N141I mutation. The gene editing data confirm that there was a robust consistency of mutation-related changes that characterized all the expected findings and genotypes from all cells.

**Additional files**

**Additional file 1: Table S1.** Antibodies, Species, Titers, and Vendors Used in this Study. (DOC 31 kb)

**Additional file 2: Figure S1.** Quality control of iPSC lines. (A) Immunofluorescence shows expression of pluripotency markers SSEA4, Nanog, Tra160 and in 7889(S)B iPSC line. (B) Three germ layers from teratomas generated by 7889(S)B iPSC line. (TIFF 1753 kb)

**Additional file 3: Figure S2** Amyloid β levels in mature BFCNs. (A) Levels of Aβ42 on BFCNs (DIV 34). *, P < .01 vs. other lines in study according to One-Way ANOVA Bonferroni Post-hoc test. (B) Levels of Aβ42 on BFCNs (DIV 34). n = 3, 3 independent experiments with technical triplicates, *, P < .01 based on Student’s T-test. (TIFF 2702 kb)

**Abbreviations**

AD: Alzheimer’s disease; ApoE: Apolipoprotein E; APP: Amyloid protein precursor; AVG: Average; Aβ: Amyloid beta; BDNF: Brain derived neurotrophic factor; BF1: Brain factor 1; BFCNs: Basal forebrain cholinergic neurons; ChAT: Acetylcholine transferase; DAPT: N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; DIV: Days in vitro; DNA: Deoxyribonucleic acid; DBPS: Dulbecco’s phosphate-buffered saline; DPBST: Dulbecco’s phosphate-buffered saline + 0.1% Triton X-100; EGTA: Ethylene-bis(oxyethylenenitriilo)tetracetic acid; EOAD: Early onset familial Alzheimer’s disease; ESC: Embryonic stem cells; FACS: Fluorescence-activated cell sorting; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GFP: Green fluorescent protein; HDR: Homology directed repair; HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol; HRP: horseradish peroxidase; iPSCs: Induced pluripotent stem cells; LDH: Lactate dehydrogenase; MAP2: Microtubule-associated protein 2; MGE: Medial ganglionic eminences; NEBs: Neuronal Embryoid Bodies; NGF: Nerve growth factor; NLRP2: NLR family pyrin domain containing 2; NPC: Neural progenitor cells; PFA: Paraformaldehyde; PSEN: Presenilin; RNA: Ribonucleic acid; ROCK: Rho-associated, coiled-coil containing protein kinase; RT: Reverse Transcriptase; RT-qPCR: Real-time quantitative polymerase chain reaction; SAG: Smoothened agonist; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis; SEM: Standard error of the mean; sgRNA: Single guide RNA; Shh: Sonic hedgehog; SNP: Single nucleotide polymorphism; SOD1N: Single stranded oligonucleotides; TBST: Tris-buffered saline + 0.1% Tween; VACht: Vesicular acetylcholine transporter; WT: Wild type

**Funding**

This work is generously supported by grants to Scott Noggle by the Charles Evans Foundation, the Alzheimer’s Drug Discovery Foundation, and The NY Community Trust. Scott Noggle and Sam Gandy were jointly supported by the Cure Alzheimer’s Fund and by National Institutes of Health (NIH) grants R21AG042965 and U01AG046170 (to Eric Schadt, Bin Zhang, Sam Gandy, and Michelle Ehrlich). Sam Gandy was also supported by The Werber Family Foundation, the Scott and Jennifer Moskowitz Foundation, the Stuart Katz and Dr Jane Martin Foundation, the Louis B. Mayer Foundation, the Georgianne and Dr. Reza Khabib Foundation, and the Sarah and Gideon Gartner Foundation. Bin Zhang, Michelle Ehrlich, and Eric Schadt were supported by U01AG046170 (to Eric Schadt, Bin Zhang, Sam Gandy, and Michelle Ehrlich). Ottavio Arancio was supported by NIH grant NS049442. Rudolph Tanzi was supported by Cure Alzheimer’s Fund. Maitaine Ortiz-Virumbrales was supported by The Werber Family Foundation and U01AG046170. Cesar Moreno was supported by Mount Sinai Alzheimer’s Disease Research Center P50 AG05138 to Mary Sano.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

**Authors’ contributions**

MOV and CLM designed, performed, analyzed and interpreted in vitro assays. MOV, CLM and SG wrote the manuscript. IK performed electrophysiological studies. MOV and PM cloned CRISPR/Cas9 constructs. MOV, CLM and PM generated CRISPR/Cas9-corrected lines. AS and SJ contributed to optimization of BFCN differentiation protocol. MZ
performed FACS sorting procedures. DP reprogrammed iPSC lines and assured QC. OA provided Aβ oligomers. RET, BZ, EES, MEE, RET, OA, SN and 5G contributed to data interpretation and manuscript editing. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Prior to their participation, all donors of skin biopsies provided their written informed consent and study approval was obtained from Western Institutional Review Board.

Consent for publication
All authors declare their consent for publication of this manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurology, NFL Neurocare Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 2Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 3The New York Stem Cell Foundation Research Institute, New York, NY, USA. 4Universidad Francisco de Vitoria, 28223 Pozuelo de Alarcón, Madrid, Spain. 5Present Address: Taub Institute and the Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. 6Department of Genetics and Genomic Sciences, Icahn Institute for Multi-Scale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 7Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 8Genetics and Aging Unit, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA. 9Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.

Received: 25 August 2017 Accepted: 16 September 2017
Published online: 27 October 2017

References
1. Arendt T, Bigl V, Arendt A, Tennstedt A (1988) Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol 61:101–108
2. Arjoni E, Gonzalez C, Shahnawaz M, Flores A, Davis B, Soto C (2017) Increased susceptibility to Aβ toxicity in neuronal cultures derived from familial Alzheimer's disease (PSEN1ΔE286) induced pluripotent stem cells. Neurobiol Lett 639:74–81. doi:10.1016/j.neulet.2016.12.069
3. Bandy C, van den Hurk M, Eames T, Marchand C, Hernandez RV, Kellogg M, Boyer L, Simon S, Gage FH (2015) Neuronal medium that supports basic survival functions and activity of human neurons in vitro. Proc Natl Acad Sci U S A 112:E2725–E2734. doi:10.1073/pnas.1504939112
4. Bissonnette CJ, Lyas L, Bhattacharyya BJ, Belmadani A, Miller RJ, Kessler JA (2011) The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells 29:802–811. doi:10.1002/stem.626
5. Boschert DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Siouda SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939–945. doi:10.1016/S0896-6273(00)80974-5
6. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hyposia in senile dementia and other abiotrophies. Brain 99:459–496
7. Bigi A, Sisodia SS, Yang W, Tamashiro K, Hsia W, Davidson RM, Tamminga CA, Hardaway JM, White RL, Kessler JA, et al. (2014) The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells 32:2109.e1-2109.e12. doi:10.1002/stem.626
8. Briggs CA, Schneider C, Richardson JC, Stutzmann GE (2013) Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. Neurobiol Aging 34:1632–1643. doi:10.1016/j.neurobiolaging.2012.12.013
9. Brown JT, Chin J, Leiser SC, Pangalos MN, Randall AD (2011) Altered intrinsic neuronal excitability and reduced Na+ currents in a mouse model of Alzheimer's disease. Neurobiol Aging 32:2109.e1-2109.e14. doi:10.1016/j.neurobiolaging.2011.05.025
10. Brueggen K, Dyrbta M, Bankoff F, Hauser L, Filippi M, Nestor PJ, Hauenstein K, Klopel S, Grotte MJ, Kasper E, Teipel SJ (2015) Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment – a multicenter DTI and Volumetry study. J Alzheimers Dis 48:197–204. doi:10.3233/JAD-150063
11. Bruey JM, Bruey-Sedano N, Newman R, Chandler S, Stehlik C, Reed JC (2004) PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-kappaB and caspase-1 activation in macrophages. J Biol Chem 279:51897–51907. doi:10.1074/jbc.M407641200
12. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27:275–280. doi:10.1038/nbt.1529
13. Chu VT, Webster T, Wefers B, Wurst W, Sander S, Rajevsky K, Kuhn R (2015) Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 33:543–548. doi:10.1038/nbt.3198
14. Codolo G, Ploteher N, Pozzobon T, Brcaule M, Tessari I, Bubacco L, de Berardinis F, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. doi:10.1126/science.1231143
15. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Thomas W, Rossvoll H, Orman MA, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921–923
16. Copeland LA, Byrne ML, Taylor H, Kerrigan TL, Bruc-Mercier G, Badger JL, Barbuti PA, Jo J, Tyler SJ, Allen SJ, Kunath T, Cho K, Caldwell MA (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. Stem Cell Res 11:206–212. doi:10.1016/j.scr.2013.08.002
17. Cummings DM, Liu W, Porter TD, Bryam S, Yaswoia M, Ho S-H, Smits H, Ali SS, Steinberg R, Pegasico C-M, James OT, Matarin M, Richardson JC, Zetterberg H, Blemnno K, Hardy JA, Salih DA, Edwards FA (2015) First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression. Brain 138:1992–2004. doi:10.1093/brain/awv127
18. Danjo T, Eiraku M, Muguruma K, Watanabe K, Kawada M, Yanagawa Y, Rubenstein JR, Sasai Y (2011) Subregional specification of embryonic stem cell-derived ventral Telencephalic tissues by timed and combinatory treatment with extrinsic signals. J Neurosci 31:1919–1933. doi:10.1523/ JNEUROSCI.0512-10.2011
19. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (London, England) 2:1403
20. Davies KL, Mohs RC, Davis BM, Horvath TB, Greenwald BS, Rosen WG, Levy ML, Johns CA (1985) Oral physostigmine in Alzheimer's disease. Psychopharmacol Bull 19:451–453
21. De Strooper B After Solanezumab: Where Should Alzheimer's Research Go? | ALZFORUM. 2017
22. Echeverria V, Berman DE, Arancio O (2007) Oligomers of beta-amylloid peptide inhibit BDNF-induced arc expression in cultured cortical neurons.Curr Alzheimer Res 4:318–321
23. Eppelbaum S, Genthon R, Cavedo E, Habert MO, Lamari F, Gagliardi G, Lista S, Telchmann M, Bakardjian H, Hampel H, Dubois D (2017) Predclinal Alzheimer's disease: a systematic review of the cohorts underlying the concept. Alzheimers Dement. doi:10.1016/j.jalz.2016.12.003
24. Etcheberriarey G, Ito E, Kim CS, Alkon DL (1994) Soluble beta-amyloid peptide induces BDNF mRNA expression in cultured neurons. Neuroscience 56:447–455
25. Ewals KM, Zetterberg H, Blennow K, Hardy JA, Salih DA, Edwards FA (2015) First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression. Brain 138:1992–2004. doi:10.1093/brain/awv127
26. Flandin P, Zhao Y, Vogt D, Jeong J, Long J, Potter G, Westphal H, Rubenstein JR (2013) Lhx6 and Lhx8 coordinately induce neuronal expression of Shh that controls the generation of interneuron progenitors. Neuron 70:939–950. doi:10.1016/j.neuron.2011.04.020
27. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147. doi:10.1136/JNIPP.66.137
28. Gamzu ER, Thal LJ, Davis KL (1990) Therapeutic trials using tacrine and other cholinesterase inhibitors. Adv Neurol 51:241–245
29. Gandy S, Doeven MK, Poolman B (2006) Alzheimer disease: presenilin springs a leak. Nat Med 12:1121–1123. doi:10.1086/nm1003
30. Goublou AL, Alden D, Davis RP, Micalef SJ, Ng ES, Yu QC, Lim SM, Soh C-L, Elliott DA, Hatzistavrou T, Bouke J, Watmuff B, Lang RL, Haynes JM, Pouton CW, Gardiol A, Trounson AO, Anderson SA, Stanley EG, Elefanty AG (2011) A targeted NOD2 human embryonic stem cell reporter line enables identification of human basal forebrain derivatives. Stem Cells 29:462–473. doi:10.1002/stem.587
31. Guo Q, Fu W, Holtzberg FW, Steiner SM, Mattson MP (1999) Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations. J Neurosci Res 56:457–470. doi:10.1002/(SICI)1097-4547(19990601)56:3<457::AID-JNEUROSCI1021>3.0.CO;2-P
32. Gustot A, Gallea JL, Sarroukh R, Celej RS, Ruyschaert JM, Raussens V (2015) Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J 471:323–333. doi:10.1042/BCJ20150167
33. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM (2014) Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat 10:391–401. doi:10.2147/NPDT.S27099
34. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT (2008) The NALP1 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 9:857–865. doi:10.1038/ni163
35. Heine WM, Giesea A, Chapin C, Ballard P, Chen JK, Routwich DH (2011) A small-molecule smoothelin antagonist prevents Glucocorticoid-induced neuronal Cerebellar injury. Sci Transl Med 3:130ra104. doi:10.1126/scitranslmed.3002731
36. Hixon JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548. doi:10.1093/pm/320.3.541
37. Hou Y, Qu Z, Cao S, Li Q, Ma L, Krencik R, Xu M, Liu Y (2016) Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci 36:1333–1343. doi:10.1523/JNEUROSCI.4501-14.2015
38. Hu Y, Qu Z, Cao S, Li Q, Ma L, Krencik R, Xu M, Liu Y (2016) Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci 36:1333–1343. doi:10.1523/JNEUROSCI.4501-14.2015
39. Ito M, Tomita T, Maruyama K, Saito TC, Iwatsubo T, Capell A, Walter J, Grüngberg J, Ueyama Y, Haass C, Ihara Y (1998) Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J Neurochem 71:313–322. doi:10.1002/jnc.490710117
40. Iwakiri W, Yamamoto S, Hasegawa M, Iramiya R, Tada S (2005) PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-activator diazoxide ameliorates amyloid-β pathology in a mouse model of Alzheimer’s disease. J Biol Chem 280:22339–22347. doi:10.1074/jbc.M100077200
41. Kawasaki T, Wang K, Kawasaki H, Hongo J, Oda S, Ono Y, Oda S, Hori H, Tanaka T, Yonekawa K, Okada K, Tanaka Y, Kubota A, Hoshino H, Kimura H, Seki K, Kawasaki M, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Suzuki K, Nakamura K, Kojima J, Kato Y, Hasegawa M, Nakashima H, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanishi Y, Yasuda K, Maruyama K, Ito H, Tanaka M, Nakanish
